| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ligand Pharmaceuticals Inc (LGND) has 11 insiders with recent SEC Form 4 filings, including 0 buys and 13 sells. LGND is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 161.3K | $35.72M | - | |
| Dir | 44.0K | $9.74M | - | |
| Dir | 33.8K | $7.48M | - | |
| Dir | 32.8K | $7.25M | - | |
| Other | 30.8K | $6.82M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2018 | Berkman Charles S81 | SVP, Gen. Counsel &Secretary | Sale+OE | 2,813 | $250.69 | $705,181.41 | -9.2% | |
| Sep 4, 2018 | Foehr Matthew W72 | President And COO | Sale+OE | 12,000 | $255.01 | $3,060,081.60 | -10.4% | |
| Sep 4, 2018 | Lamattina John L | Director | Sale+OE | 3,335 | $254.96 | $850,291.93 | -13.5% | |
| Sep 4, 2018 | Sabba Stephen L | Director | Sale+OE | 5,000 | $255.05 | $1,275,250.00 | -15.7% | |
| Sep 4, 2018 | Berkman Charles S81 | SVP, Gen. Counsel &Secretary | Sale+OE | 19,417 | $254.99 | $4,951,065.10 | -41.2% | |
| Aug 30, 2018 | Higgins John L66 | Chief Executive Officer | Sell | 3,500 | $258.25 | $903,875.00 | -3.9% | |
| Aug 29, 2018 | Korenberg Matthew E | EVP,Finance &Strategy And CFO | Sale+OE | 18,357 | $256.69 | $4,712,060.17 | -73.1% | |
| Aug 17, 2018 | Aryeh Jason | Director | Sell | 27,942 | $241.94 | $6,760,159.32 | -17.7% | |
| Aug 17, 2018 | Davis Todd C77 | Director | Sell | 9,000 | $239.78 | $2,158,001.77 | -8.8% | |
| Aug 17, 2018 | Higgins John L66 | Chief Executive Officer | Sale+OE | 34,500 | $241.96 | $8,347,559.65 | -16.2% |